A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
aspirin_0709 6/24/09 2:16 PM Page 2 30 Renal & Urology News JULY 2009 Regimen Prolongs AV Graft Patency Aspirin plus dipyridamole decreased the risk of primary unassisted patency loss by 18% BY TRACI DANTONI “Our trial results show that we now “This is an important step forward ing order so patients can get the A COMBINATION of aspirin and have a drug therapy that significantly as we proceed to develop therapies dialysis they need,” said Griffin P. the antiplatelet drug dipyridamole prolongs the viability of AV grafts,” to improve dialysis patients’ quality Rodgers, MD, Director of the can significantly decrease the risk said lead investigator Bradley S. of life.” National Institute of Diabetes and of patency loss in new arterioven- Dixon, MD, Associate Professor of “This drug combination provides a Digestive and Kidney Diseases, which ous (AV) hemodialysis (HD) grafts, Medicine at the University of Iowa modest but important new therapy supported the trial. “But clearly according to a five-year study. College of Medicine in Iowa City. to keep AV grafts in good work- more research is needed to ex- tend the useful life of AV grafts.” Study findings appear in The New England Journal of Medicine (2009; 360:2191-2201). Conducted at 13 clinical sites in the United States, the study involved 649 HD patients who recently re- ceived an AV graft. Subjects were randomly assigned to receive dipy- ridamole 200 mg plus aspirin 25 mg twice daily (321 patients) or a place- bo (328 patients) over 4.5 years, with six additional months of follow-up. The combination did not raise the incidence of severe adverse events. The median duration of patency was 5.8 months in the combined-treatment arm compared with 4.3 months in
Pages to are hidden for
"Regimen Prolongs AV Graft Patency"Please download to view full document